{"filing":{"accession_number":"0001628280-26-053817","cik":"0001822462","ticker":"FHTX","company_name":"Foghorn Therapeutics Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"fhtx-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1822462/000162828026053817/fhtx-20260806.htm"},"events":[{"id":25852,"run_id":23470,"accession_number":"0001628280-26-053817","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.94,"summary":"Foghorn Therapeutics disclosed financial results for the quarter ended June 30, 2026, including collaboration revenue of $16.1 million, R\u0026D expenses of $18.5 million, net loss of $7.2 million, and cash position of $167.6 million, with cash runway guidance into H1 2028. The disclosure was made via press release (Exhibit 99.1) and investor presentation (Exhibit 99.2) furnished under Items 2.02 and 7.01.","company_name":"Foghorn Therapeutics Inc.","ticker":"FHTX","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26783,"accession_number":"0001628280-26-053817","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses Foghorn Therapeutics' financial results for the quarter ended June 30, 2026, including collaboration revenue of $16.1 million, R\u0026D expenses of $18.5 million, net loss of $7.2 million, and cash position of $167.6 million. The press release (Exhibit 99.1) is a standard earnings announcement with condensed consolidated financial statements and operational updates, typical of Item 2.02 earnings releases.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:38:41.650058+00:00","company_name":"","ticker":null,"filing_date":""},{"id":26784,"accession_number":"0001628280-26-053817","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Item 7.01 disclosure furnishes an investor presentation (Exhibit 99.2) alongside a substantive earnings press release (Exhibit 99.1) dated August 6, 2026, providing second quarter 2026 financial and corporate updates. The press release includes condensed consolidated balance sheets and statements of operations for Q2 2026, collaboration revenue of $16.1 million, net loss of $7.2 million, and cash runway guidance into H1 2028—all hallmarks of a quarterly earnings disclosure. Although Item 7.01 is technically a Regulation FD disclosure, the core material event is the earnings release itself.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:38:41.650058+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26783,"accession_number":"0001628280-26-053817","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The filing discloses Foghorn Therapeutics' financial results for the quarter ended June 30, 2026, including collaboration revenue of $16.1 million, R\u0026D expenses of $18.5 million, net loss of $7.2 million, and cash position of $167.6 million. The press release (Exhibit 99.1) is a standard earnings announcement with condensed consolidated financial statements and operational updates, typical of Item 2.02 earnings releases.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:38:41.650058+00:00","company_name":"Foghorn Therapeutics Inc.","ticker":"FHTX","filing_date":"2026-08-06"},{"id":26784,"accession_number":"0001628280-26-053817","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Item 7.01 disclosure furnishes an investor presentation (Exhibit 99.2) alongside a substantive earnings press release (Exhibit 99.1) dated August 6, 2026, providing second quarter 2026 financial and corporate updates. The press release includes condensed consolidated balance sheets and statements of operations for Q2 2026, collaboration revenue of $16.1 million, net loss of $7.2 million, and cash runway guidance into H1 2028—all hallmarks of a quarterly earnings disclosure. Although Item 7.01 is technically a Regulation FD disclosure, the core material event is the earnings release itself.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:38:41.650058+00:00","company_name":"Foghorn Therapeutics Inc.","ticker":"FHTX","filing_date":"2026-08-06"}]}